Skip to main content
    M

    MannKind Corp (MNKD)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $3.96
    -0.18 (-4.24%)

    Market Cap: $1.33B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    MannKind Corp (MNKD) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to MannKind are MoonLake Immunotherapeutics (MLTX), Structure Therapeutics Inc. American Depositary Shares (GPCR) and MBX Biosciences, Inc. Common Stock (MBX). By market cap, MannKind ranks 8th of the 13 companies on this page; MBX Biosciences, Inc. Common Stock (MBX) is the largest at $2.78B.

    Peer Comparison

    MNKD's ROIC of -10.4% is above the peer median of -34.9%, and its revenue growth of 24.0% is above the median of 0.0%. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    MannKind (MNKD)$1.33BN/A3.1x-18.1%-10.4%24.0%0.00%
    MoonLake Immunotherapeutics (MLTX)$1.06BN/AN/A0.0%-54.6%0.0%0.00%
    Structure Therapeutics Inc. American Depositary Shares (GPCR)$1.43BN/AN/A0.0%N/A0.0%0.00%
    MBX Biosciences, Inc. Common Stock (MBX)$2.78BN/AN/A0.0%N/A0.0%0.00%
    Omeros Corporation (OMER)$1.27BN/A16.4x324.9%33.6%14.9%0.00%
    Inhibrx Biosciences, Inc. (INBX)$1.23BN/A610.4x0.0%-66.0%-100.0%0.00%
    Nurix Therapeutics Inc (NRIX)$1.69B6.4x2.3x42.0%N/A8426.0%0.00%
    Prime Medicine, Inc. Common Stock (PRME)$949.85MN/A105.5x0.0%N/A243.9%0.00%
    Nuvation Bio Inc (NUVB)$1.41BN/A6.7x-67.4%-18.7%242.6%0.00%
    Innoviva Inc (INVA)$1.35B5.3x3.0x44.1%10.8%-1.6%0.00%
    Nektar Therapeutics (NKTR)$1.27BN/A23.9x0.0%N/A-20.4%0.00%
    Mineralys Therapeutics, Inc. Common Stock (MLYS)$1.36BN/AN/A0.0%-51.1%0.0%0.00%
    Vir Biotechnology Inc (VIR)$1.71BN/A5.4x-61.0%N/A19582.0%0.00%
    Peer median$1.36B5.8x11.6x0.0%-34.9%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to MannKind, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    MoonLake Immunotherapeutics (MLTX)
    MoonLake Immunotherapeutics is an innovative biotechnology firm dedicated to advancing therapies for chronic inflammatory diseases through its proprietary drug...
    MLTX competitors
    Structure Therapeutics Inc. American Depositary Shares (GPCR)
    Structure Therapeutics Inc., a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic...
    GPCR competitors
    MBX Biosciences, Inc. Common Stock (MBX)
    MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment...
    MBX competitors
    Omeros Corporation (OMER)
    Omeros Corporation, a commercial-stage biopharmaceutical company, discovers, develops, and markets protein and small molecule therapies...
    OMER competitors
    Inhibrx Biosciences, Inc. (INBX)
    Inhibrx, Inc., a clinical-stage biotechnology company, is focused on developing a line of new biological therapeutic candidates.
    INBX competitors
    Nurix Therapeutics Inc (NRIX)
    Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development...
    NRIX competitors
    Prime Medicine, Inc. Common Stock (PRME)
    Prime Medicine, Inc. is a pioneering biotechnology company specializing in genetic medicine through its proprietary Prime Editing technology...
    PRME competitors
    Nuvation Bio Inc (NUVB)
    Nuvation Bio Inc., a clinical-stage biopharmaceutical company, is focused on developing therapeutic candidates for oncology.
    NUVB competitors
    Innoviva Inc (INVA)
    Innoviva, Inc. is dedicated to the development and commercialization of pharmaceutical products. The company is headquartered in Burlingame, California.
    INVA competitors
    Nektar Therapeutics (NKTR)
    Nektar Therapeutics is a biopharmaceutical company.
    NKTR competitors
    Mineralys Therapeutics, Inc. Common Stock (MLYS)
    Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and associated cardiovascular...
    MLYS competitors
    Vir Biotechnology Inc (VIR)
    Vir Biotechnology, Inc., a clinical-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases.
    VIR competitors

    Frequently Asked Questions About MNKD

    Who are MannKind's main competitors?

    The companies most similar to MannKind include MoonLake Immunotherapeutics (MLTX), Structure Therapeutics Inc. American Depositary Shares (GPCR), MBX Biosciences, Inc. Common Stock (MBX), Omeros (OMER) and Inhibrx Biosciences (INBX), listed from the closest match.

    Who is MannKind's biggest competitor?

    MBX Biosciences, Inc. Common Stock (MBX) is the largest of the similar companies at $2.78B; MoonLake Immunotherapeutics (MLTX) is the closest match by business profile, size, sector and industry.

    How does MNKD stock compare with its competitors?

    MNKD's P/S is 3.1x against a peer median of 11.6x; its net margin is -18.1% against a peer median of 0.0%.

    Which of MannKind's competitors pays a higher dividend?

    MannKind pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is MannKind bigger than its competitors?

    No. MannKind is 8th by market cap among the 13 companies on this page; the largest is MBX Biosciences, Inc. Common Stock (MBX) at $2.78B.